Tom is a US/Canadian intellectual property (IP) and transaction attorney with 25+ years’ experience in global IP asset management. His clients are R&D stage life-science startups and their venture investors. He practiced 10+ years at Novartis in Cambridge (MA) and Basel, Switzerland.
Tom provides a worldwide perspective on IP strategy to achieve licensing, M&A and commercialization objectives. Tom’s work includes integration with critical regulatory data exclusivities (e.g. Hatch-Waxman) that overlap with patents to determine generic entry date. Freedom-to-operate investigation and analysis is a critical aspect of strategic planning. Tom also has deep experience in complex global IP issues relating to IP enforcement and litigation, tax, transfer-pricing, supply-chain management and compliance with trade-sanction rules.
DigbyGlobal prepares an early stage life science project for stand-alone success and for seamless integration with potential pharma partners.
-Securing patents, protecting know-how -Freedom-to-operate analysis -Patent avoidance/Design-around strategy -International trade sanctions (IP aspects) -IP enforcement strategy -Pharmaceutical life-cycle management/Generic entry planning -Royalty-rate comparables for license agreements and damage/settlement calculations